Prescience Point Capital Management Raises Price Target on MiMedx Group to $31 Per Share
Prescience Point Capital Management Raises Price Target on MiMedx Group to $31 Per Share New Research Indicates That MiMedx's Amniofix Injectable Product Will Be A Blockbuster, Game-Changing Treatment for Knee Osteoarthritis MiMedx's Wound Care Sales Are Poised To Re-Accelerate Over The Coming Quarters Due To Recent Contract And Insurance Wins And A New Product Launch News provided by Share this article Share this article BATON ROUGE, La., Dec. 16, 2020 /PRNewswire/ -- Prescience Point Capital Management, a research-focused, catalyst-driven investment firm, today announced it has issued new ...
Source: prnewswire.com